Hepatitis C News

WASHINGTON — Vosevi, a triple-combination therapy for chronic hepatitis C virus infection, was effective when used as a rescue treatment in patients who did not achieve sustained virologic response with direct-acting antiviral agents.

WASHINGTON — In this video, John Ward, MD, director of the Coalition for Global Hepatitis Elimination at the CDC Taskforce for Global Health, details the need for hepatitis C prevention and treatment options for injection-drug users.

WASHINGTON — In this video, John Ward, MD, director of the Coalition for Global Hepatitis Elimination at the CDC Taskforce for Global Health, discusses the need for a national commitment to a hepatitis C elimination program.

WASHINGTON — In this video, John Ward, MD, director of the Coalition for Global Hepatitis Elimination at the CDC Taskforce for Global Health, discusses successes and challenges in hepatitis elimination at The Liver Meeting.

WASHINGTON — In this video, Tatyana Kushner, MD, associate professor in the division of liver diseases at the Icahn School of Medicine at Mount Sinai, discusses the benefits of patient inclusion and participation at The Liver Meeting.

WASHINGTON — Although well-established and effective treatment protocols exist for most patients with hepatitis C virus infection, a presenter at The Liver Meeting said uncertainty remains when treating pregnant people with HCV.

WASHINGTON — A special interest group session at The Liver Meeting focused on challenges in treating patients with hepatitis C virus, as well as disparities in access to care.

WASHINGTON — A number of presentations, lectures and posters at The Liver Meeting focused on hepatitis C virus and work being done to achieve the WHO goal for elimination by 2030, according to an expert in attendance.

WASHINGTON — The risk for hepatitis C virus reinfection after direct-acting antiviral therapy was high in people with recent injection drug use, while antipsychotic drugs and opioid agonists offered possible protective effects.

WASHINGTON — A decentralized, integrated care model is necessary to eradicate hepatitis C virus in hard-to-reach populations, including among individuals who use drugs, according to a presenter at The Liver Meeting.